Tyra Biosciences Balance Sheet Health
Financial Health criteria checks 5/6
Tyra Biosciences has a total shareholder equity of $376.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $392.5M and $16.4M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$373.80m |
| Equity | US$376.04m |
| Total liabilities | US$16.42m |
| Total assets | US$392.46m |
Recent financial health updates
Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation
Aug 29
We're Not Very Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Rate
May 13We're Not Very Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Rate
Jan 13We Think Tyra Biosciences (NASDAQ:TYRA) Can Afford To Drive Business Growth
Sep 27Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans
Jun 13Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans
Feb 23Recent updates
Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation
Aug 29Lots Of Bullish Signals, But No Revenue Or Earnings From Tyra Biosciences
Jul 23A Look At The Intrinsic Value Of Tyra Biosciences, Inc. (NASDAQ:TYRA)
Jul 05We're Not Very Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Rate
May 13We're Not Very Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Rate
Jan 13We Think Tyra Biosciences (NASDAQ:TYRA) Can Afford To Drive Business Growth
Sep 27Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans
Jun 13Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans
Feb 23Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans
Nov 09Tyra Biosciences GAAP EPS of -$0.36
Aug 04Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation
Jul 21Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation
Mar 31Companies Like Tyra Biosciences (NASDAQ:TYRA) Are In A Position To Invest In Growth
Dec 15Financial Position Analysis
Short Term Liabilities: TYRA's short term assets ($378.6M) exceed its short term liabilities ($10.4M).
Long Term Liabilities: TYRA's short term assets ($378.6M) exceed its long term liabilities ($6.0M).
Debt to Equity History and Analysis
Debt Level: TYRA is debt free.
Reducing Debt: TYRA has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TYRA has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if TYRA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.